# Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment

> **NCT00672581** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (estimated)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** ZD4054

## Key facts

- **NCT ID:** NCT00672581
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** —
- **Final completion:** 2009-03
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2010-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00672581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00672581, "Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00672581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*